NCT06661902View on ClinicalTrials.gov

Buffered Lidocaine for Reducing Pain in Patients Undergoing Prostate Biopsy, BURN Trial

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

January 9, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Prostate Cancer
Interventions
DRUG

Buffered Lidocaine (1% Lidocaine + 8.4% Sodium Bicarbonate, in a 3:1 ratio)

Given via injection

DRUG

Lidocaine

Given via injection

PROCEDURE

Biopsy of Prostate

Undergo SOC prostate biopsy

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

98195

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
lead

University of Washington

OTHER